Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
The National Bone Health Alliance (NBHA), a public-private partnership with 42 member organizations, is urging a simple solution to a big problem: if it’s 50+ fracture, request a test. This is the call-to-action for the NBHA’s new public and healthcare professional education campaign – 2Million2Many (www.2Million2Many.org).
The campaign reflects the two million bone breaks that occur in the U.S. each year that are caused by osteoporosis and urges the public and healthcare professionals alike to take action and request a test for osteoporosis when someone age 50 or older breaks a bone. Despite the fact that 50 percent of osteoporosis-related repeat fractures can be prevented with existing treatments, only two in 10 initial bone breaks get a follow-up test or treatment for osteoporosis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56192-national-bone-health-alliance-nbha-prevent-osteoporosis-2million2many
Allergan, Inc. (NYSE: AGN), the makers of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced today the launch of the LATISSE® Wishes Challenge campaign. Inspired by the tradition of blowing on an eyelash to make wishes come true, lifestyle designer Kathy Ireland, professional ballroom dancer Chelsie Hightower and style guide Bobbie Thomas will each lead teams of LATISSE® users from across the country who are challenged to raise more than a quarter of a million dollars for the Make-A-Wish Foundation, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® solution is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/latisse/43354/
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Singing sensation Justin Bieber is speaking out as a huge fan – and has just been named a spokesperson – of Proactiv®, America’s #1 acne system. Bieber will talk to teens about being proactive about acne and skin care to prevent breakouts as part of the brand’s unique Be Proactiv® marketing campaign.
For more information, go to http://www.multivu.com/players/English/45556-Justin-Bieber-Proactiv-Spokesperson/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
As many as one in five U.S. teens suffers from disabling mental illness. Throughout Mental Health Awareness Month in May, BeSmartBeWell.com highlights the issue of mental illness in teens and tells the stories of two teens who moved from diagnosis through treatment and recovery.
What does mental illness look like in teens? It looks like Colleen, who’s battled depression and anxiety since she was 13, and Katie, who struggled with addiction in her early teens. Mental illness in teens looks just like the kid next door – studies show nearly half of all youth will experience a mental disorder at some point in their lives.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50033/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
